Business Model & Revenue
Ironwood is a gastrointestinal-focused biotech with one of the cleanest commercial models in specialty pharma. LINZESS (linaclotide), the U.S. branded prescription market leader in IBS-C and chronic idiopathic constipation, is co-promoted under a 50/50 U.S. brand collaboration with AbbVie: AbbVie books net sales ($324.9 million in Q3) and the partners split brand profits after commercial and R&D costs ($255.9 million in Q3, a 79.8% commercial margin), with Ironwood recording its share as collaboration revenue. Ex-U.S. partners — AbbVie (CONSTELLA in Europe), Astellas (Japan) and Grand Life Sciences (China) — contribute smaller royalty streams.
The company runs lean at roughly 100 employees, which is why $133 million of quarterly revenue converts to $97.9 million of Adjusted EBITDA and why operating cash flow reached $130.8 million in Q3 alone. Capital priority in 2026 has been simplification: the $200 million convertible note repayment left a debt-light balance sheet. Growth capital goes to apraglutide, a once-weekly long-acting GLP-2 analog acquired with VectivBio and now in the STARS-2 confirmatory Phase 3 for short bowel syndrome with intestinal failure, plus earlier-stage GC-C programs such as IW-3300.
Financial Highlights
Q3 2026 Results (Quarter Ended September 30, 2026)
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Total revenue | $133.0M | $122.1M | +8.9% |
| LINZESS collaboration revenue | $129.9M | $119.6M | +8.6% |
| GAAP net income | $59.8M | $40.1M | +49% |
| Diluted EPS | $0.36 | $0.23 | +57% |
| Adjusted EBITDA | $97.9M | $81.8M | +20%, record |
| Operating cash flow | $130.8M | $47.6M | +175% |
Q3 2026 vs Consensus
| Metric | Reported | Consensus | Beat |
|---|---|---|---|
| EPS | $0.36 | $0.33 | +$0.03 |
Quarterly Progression
| Quarter | Total Revenue | GAAP Net Income | Adjusted EBITDA | LINZESS U.S. Net Sales |
|---|---|---|---|---|
| Q1 2026 | $107M | $41M | $77M | $273M |
| Q2 2026 | $113M | $51M | $83M | $282M |
| Q3 2026 | $133M | $59.8M | $97.9M | $324.9M |
Annual Context
| Metric | FY 2025 | FY 2026 Guidance |
|---|---|---|
| Total revenue | $296.2M | $485-510M |
| LINZESS U.S. net sales | Below $880M | $1.20-1.25B |
| Adjusted EBITDA | n/d | >$350M |
Year-to-date U.S. LINZESS net sales of $880 million already exceed full-year 2025.
Balance Sheet Snapshot (September 30, 2026)
| Item | Amount |
|---|---|
| Cash and equivalents | $86.4M (vs $215.5M at YE 2025) |
| Convertible notes | $200M repaid in Q2 2026 with cash |
| Accounts receivable | $132.7M |
| Shares outstanding | 165.24M |
Guidance: raised from LINZESS U.S. $1.15-1.20B / revenue $460-485M / Adjusted EBITDA >$310M to $1.20-1.25B / $485-510M / >$350M.
Competitive Landscape
Ironwood occupies a profitable niche: it monetizes the leading U.S. brand in a category (IBS-C/CIC) where prescribers default to first-line therapy, while spending a fraction of a typical commercial pharma footprint because AbbVie carries the field force. Direct competition comes from other branded GI secretagogues and prokinetics.
- AbbVie (ABBV): partner, not just competitor — controls LINZESS U.S. commercialization and books net sales, but also owns a broad GI portfolio and sits across the table on the 50/50 economics; the relationship is the business.
- Ardelyx (ARDX): IBRELA (tenapanor) is the closest branded head-to-head in IBS-C and CIC, with XPHOZAH adding a phosphate-control franchise; Ardelyx is commercial-stage with its own launch momentum.
- Salix / Bausch Health (BHC): Trulance (plecanatide), the other GC-C agonist franchise in constipation disorders, backed by a dedicated GI salesforce.
- Takeda (TAK): Motegrity (prucalopride) and a deep GI portfolio compete for the same prescriber base in motility disorders.
- Teva (TEVA): the looming generic threat — patent settlements license U.S. generic linaclotide entry no earlier than March 2029, and Teva's scale makes it the marginal competitor that resets pricing after the cliff.
Moats: (1) LINZESS is the #1 prescribed U.S. brand in its category per IQVIA, with 63.4 million capsules of Q3 demand growing 4.9%; (2) a settlement-fortified patent estate that contractually fixes U.S. generic entry at March 2029 or later; (3) 50/50 brand-collaboration economics that let a 100-person company harvest blockbuster-scale profits; (4) apraglutide's positive STARS Phase 3 dataset and orphan-designated SBS-IF indication, a natural successor franchise where Ironwood would own full economics.
Catalysts
- Q4 2026 earnings (expected February 2027): LINZESS tracking toward $1.20-1.25 billion sets up a potential third consecutive guidance raise; consensus sits at Buy with a $6.10 average target.
- STARS-2 execution updates through 2027: planned activation of more than 100 sites in 22 countries for the confirmatory Phase 3 of apraglutide in SBS-IF, with management explicitly aiming to accelerate the program toward a 2029 filing.
- Capital deployment: guidance assumes no material business-development spend, so any buyback, BD tuck-in or pipeline in-licensing announcement deploys >$350 million of annual EBITDA generation the market has not priced.
- LINZESS pediatric and ex-U.S. royalty growth: demand growth in U.S. pediatrics plus CONSTELLA (EU), Japan (Astellas) and the Grand Life Sciences China launch extend the cash runway into the cliff.
- Any strategic review outcome: with a sub-$750 million equity value against >$350 million of annual EBITDA, Ironwood is a logical consolidation target for GI-focused pharma while the asset still has two-plus years of protected cash flows.
Key Risks
- Patent cliff: settlements with Teva and earlier generic filers license U.S. generic linaclotide entry no earlier than March 2029 for all three dosage strengths; roughly all of the LINZESS profit pool is exposed, and the market may keep compressing the multiple as the cliff approaches regardless of earnings delivery.
- Pipeline gap risk: apraglutide's STARS-2 confirmatory Phase 3 must activate more than 100 sites across 22 countries, with regulatory filing planned only for 2029 — any trial delay leaves a multi-year revenue hole between LINZESS loss of exclusivity and a replacement asset.
- Net-price dependence: 2026's guidance raises rest on improved LINZESS net price after the January 2026 reset; Q3 U.S. net sales grew only 3.2% year over year with a low-single-digit net price decline from unfavorable gross-to-net rebate reserves, and AbbVie controls the commercial levers.
- Single-partner concentration: essentially all revenue is the 50/50 U.S. LINZESS brand collaboration with AbbVie, with $132.7 million of the quarter-end receivables tied to that relationship; any dispute or repricing of the collaboration would be immediately material.
- Cash trajectory: cash and equivalents fell from $215.5 million at year-end 2025 to $86.4 million after the $200 million convertible repayment, and guidance assumes no material business-development spend — funding BD, a launch ramp for apraglutide, or buybacks requires trade-offs.
Our Thesis
LINZESS is on its way back to blockbuster status, and Ironwood captures half of it. After the January 2026 net-price reset, U.S. net sales grew 97% in Q1 and 44% in the first half; Q3 delivered $324.9 million with 4.9% prescription demand growth and a 79.8% commercial margin. The economics are unusually clean: Ironwood books 50% of U.S. brand-collaboration profits while AbbVie runs commercialization, operates with roughly 100 employees, generated $97.9 million of quarterly EBITDA, and retired its $200 million convertible notes with cash. Yet the stock — down from a $5.78 fifty-two-week high and near 3x forward earnings — prices the March 2029 licensed generic cliff as a total wipeout, crediting nothing for apraglutide, a next-generation GLP-2 in confirmatory Phase 3 for short bowel syndrome with intestinal failure.
On 165.24 million shares, the market cap is approximately $702 million; net of $86.4 million of cash, enterprise value is roughly $616 million — about 1.7x guided FY2026 Adjusted EBITDA of $355 million. Our $6.50 target applies 3.0x to that EBITDA: (3.0 x $355M + $86M) / 165.24M shares = $6.97, discounted for cliff timing to $6.50 — still a steep discount to the 8-10x commanded by durable specialty pharma.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.